Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMA PBSCT with Peri-Transplant Rituximab for B-Cell Lymphoid Malignancies
NCT04684979Phase 2Withdrawn
- Sponsor
- Baptist Health South Florida
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in B-cell lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Baptist Health South Florida. Planned start Mar 2022; status: withdrawn.
02
Drugs
rituximab
03
Conditions
B-cell lymphoid malignanciesdiffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04684979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684979.